公开(公告)号：US20240299587A1

公开(公告)日：2024-09-12

申请号：US18277425

申请日：2022-02-21

Applicant: Pfizer Inc.

Inventor： Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Weifeng Liu ,  Yuhang Liu

IPC: A61K49/00 ,  A61K38/16 ,  A61P31/22

CPC classification number: A61K49/0004 ,  A61K38/162 ,  A61P31/22

Abstract: The present invention relates to a method for identifying a candidate therapeutic for a disease caused by infection with a human cytomegalovirus (HCMV) having a glycoprotein B (gB) polypeptide, comprising contacting the HCMV gB polypeptide comprising a druggable region with a compound, wherein binding of said compound indicates a candidate therapeutic. The present invention also relates to candidate therapeutics comprising modulators and inhibitors of HCMV activity and pharmaceutical compositions comprising said modulators and inhibitors and methods of use thereof.

公开(公告)号：US20240100153A1

公开(公告)日：2024-03-28

申请号：US18506578

申请日：2023-11-10

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

CPC classification number: A61K39/245 ,  C07K14/045 ,  C12N7/00 ,  C12N2710/16134

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20220088184A1

公开(公告)日：2022-03-24

申请号：US17350008

申请日：2021-06-17

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US11857622B2

公开(公告)日：2024-01-02

申请号：US17350008

申请日：2021-06-17

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

CPC classification number: A61K39/245 ,  C07K14/045 ,  C12N7/00 ,  C12N2710/16134

Abstract: The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.

公开(公告)号：US11629172B2

公开(公告)日：2023-04-18

申请号：US16721229

申请日：2019-12-19

Applicant: Pfizer Inc.

Inventor： Philip Ralph Dormitzer ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Seungil Han ,  Kyle Paul Heim ,  Thomas Richard Jones ,  Yuhang Liu ,  Xiayang Qiu ,  Xinzhen Yang ,  Xiaojie Yao ,  Matthew Curtis Griffor ,  Jennifer Anne Nicki

IPC: C07K14/005 ,  A61K39/00

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20200247853A1

公开(公告)日：2020-08-06

申请号：US16721229

申请日：2019-12-19

Applicant: Pfizer Inc.

Inventor： Philip Ralph Dormitzer ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Seungil Han ,  Kyle Paul Heim ,  Thomas Richard Jones ,  Yuhang Liu ,  Xiayang Qiu ,  Xinzhen Yang ,  Xiaojie Yao ,  Matthew Curtis Griffor ,  Jennifer Anne Nicki

IPC: C07K14/005

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.